{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:41:46Z","timestamp":1791520906868,"version":"4.3.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>The discovery of the target antigen M-type phospholipase A2 receptor (PLA2R) with the possibility to detect anti-PLA2R antibodies in serum as well as the identification of several other antigens, overall accounting for almost all cases of membranous nephropathy, paved the way to a revolutionary change in the classification of membranous nephropathy. Serum anti-PLA2R autoantibody titers have been found to be highly specific diagnostic and prognostic biomarkers. Therefore, a positive test for anti-PLA2R serology in patients who present with nephrotic syndrome, normal kidney function, and no evidence of another process to account for proteinuria is believed to suffice to make a diagnosis of primary membranous nephropathy, thus removing the need for a renal biopsy. While technological advances will likely allow this proposal to prevail in the near future, the reasons why renal biopsy could still remain a critical tool for the management of membranous nephropathy in real life are discussed.<\/jats:p>","DOI":"10.1093\/ckj\/sfae292","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T03:50:58Z","timestamp":1728013858000},"source":"Crossref","is-referenced-by-count":5,"title":["The role of kidney biopsy in the diagnosis of membranous nephropathy"],"prefix":"10.1093","volume":"17","author":[{"given":"Dario","family":"Roccatello","sequence":"first","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member), Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley San Giovanni Bosco Hub Hospital, and Department of Clinical and Biological Sciences of the University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member), Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley San Giovanni Bosco Hub Hospital, and Department of Clinical and Biological Sciences of the University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-9441","authenticated-orcid":false,"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member), Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley San Giovanni Bosco Hub Hospital, and Department of Clinical and Biological Sciences of the University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"2024102109271927300_bib1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.autrev.2016.02.014","article-title":"New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature","volume":"15","author":"Roccatello","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2024102109271927300_bib2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"2024102109271927300_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2024102109271927300_bib4"},{"key":"2024102109271927300_bib5","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 Clinical Practice Guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2024102109271927300_bib6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40620-020-00781-6","article-title":"Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy","volume":"34","year":"2021","journal-title":"J Nephrol"},{"key":"2024102109271927300_bib7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic MN","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"2024102109271927300_bib8","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"key":"2024102109271927300_bib9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/ndt\/gfad227","article-title":"Membranous nephropathy-diagnosis and identification of target antigens","volume":"39","author":"Sethi","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2024102109271927300_bib10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int"},{"key":"2024102109271927300_bib11","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2215\/CJN.05480421","article-title":"Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a validation study","volume":"16","author":"Bobart","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024102109271927300_bib12","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3390\/genes14071343","article-title":"The role of PLA2R in primary membranous nephropathy: do we still need a kidney biopsy?","volume":"14","author":"McDonnell","year":"2023","journal-title":"Genes"},{"key":"2024102109271927300_bib13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"2024102109271927300_bib14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/ckj\/sfw121","article-title":"Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy","volume":"10","author":"Jullien","year":"2017","journal-title":"Clin Kidney J"},{"key":"2024102109271927300_bib15","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2024102109271927300_bib16","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s40620-024-01893-z","article-title":"Significance of the total renal chronicity score in predicting renal outcome in PLA2R-associated membranous nephropathy","volume":"37","author":"Ren","year":"2024","journal-title":"J Nephrol"},{"key":"2024102109271927300_bib17","doi-asserted-by":"publisher","first-page":"e015243","DOI":"10.1136\/bmjopen-2016-015243","article-title":"Outpatient percutaneous native renal biopsy: safety profile in a large monocentric cohort","volume":"7","author":"Roccatello","year":"2017","journal-title":"BMJ Open"},{"key":"2024102109271927300_bib18","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1177\/0961203317751645","article-title":"Safety of outpatient percutaneous native renal biopsy in systemic autoimmune diseases: results from a monocentric cohort","volume":"27","author":"Roccatello","year":"2018","journal-title":"Lupus"},{"key":"2024102109271927300_bib19","article-title":"Clinical and humanistic burden of IgAN in adult patients: a global real-world survey","author":"Tang","journal-title":"Kindey"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae292\/59573794\/sfae292.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/10\/sfae292\/59923977\/sfae292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/10\/sfae292\/59923977\/sfae292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T09:27:30Z","timestamp":1729502850000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae292\/7810269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae292","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,10,1]]},"article-number":"sfae292"}}